Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368565 | 0.90 | POLB (0.56) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL348156 | 0.82 | LMNA (0.57) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL6592804 | 0.82 | LMNA (0.61) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL1953578 | 0.82 | POLB (0.61) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL2605630 | 0.82 | LMNA (0.73) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL14070021 | 0.80 | POLB (0.79) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL375897 | 0.80 | PKM (0.59) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL4108486 | 0.80 | L3MBTL1 (0.59) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL31549975 | 0.80 | PKM (0.59) | POLBHTTNPC1CYP3A4L3MBTL1 | |
| SCHEMBL28557642 | 0.80 | LMNA (0.58) | POLBHTTNPC1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | POLB 1166/4885HTT 4/4885NPC1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.